[ Vivet Therapeutics raises $40.9M in Series A ]
Vivet Therapeutics has raised $40.9 million in Series A funding.
Founded in 2016, Vivet Therapeutics is engaged in developing and commercializing gene therapies for the treatment of liver disorders and orphan diseases.
The funds will be used by Vivet to advance a diversified pipeline of gene therapy programs targeting rare, inherited metabolic diseases, including Wilson Disease, progressive familial intrahepatic cholestasis type 2 (PFIC2), progressive familial intrahepatic cholestasis type 3 (PFIC3) and citrullinemia type I.
|Founder / CEO||Jean Philippe Combal|
|Investors||Novartis Venture Fund|
|Columbus Venture Partners|
|Roche Venture Fund|